Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 330

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 330
---
 compensation   |     |            |        1,161,650 |     |            |        1,415,397 |
| Other accrued expenses |     |            |          855,700 |     |            |          156,400 |
|                        |     | $5,170,166 |                  |     | $3,438,559 |                  |

Note 10-Convertiblepromissory notes On various dates beginning on December 11, 2023 through September 18, 2024, the Company completed a private placement in which the Company issued Convertible Promissory Notes (the “Notes”) with various entities at various amounts for an aggregate of $ 31,253,000. The Notes bear interest at a rate of twenty percent ( 20%) per annum and were scheduled to mature on the second anniversary of the issuance date. In addition, the investors in the private placement also received common stock purchase warrants (the “2024 Warrants”) in the event they subscribe to purchase Notes in the aggregate principal amount of more than $ 4.0million or more, with such number of 2024 Warrants being equal to 50% of the aggregate principal amount of the Note purchased divided by $ 3.80. The 2024 Warrants related to these Notes have an exercise price of $ 5.70per share and expire three yearsfrom the date of issuance. On October 18, 2024, under automatic conversion features upon the occurrence of a reverse public merger transaction, the convertible notes payable converted to common stock and the derivative liability was reclassified to additional paid-incapital. Conversion feature under reverse public merger transaction Under a reverse public merger transaction, the Notes convert at the sum of (a) the outstanding principal balance and unpaid accrued interest at the time of the transaction, plus (b) a Make-Whole Amount premium, defined in the Notes as additional interest to be incurred until the next period end date as defined in the Notes, divided by a conversion price equal to $ 3.80. Upon closing of the merger on October 18, 2024, the Notes were converted into shares of common stock. The Company evaluated the terms of the Notes for embedded conversion features in accordance with ASC 815-15-25and determined that the conversion features meet the definition of an embedded derivative liability that is required to be bifurcated from the host instrument and measured at fair value, with subsequent changes in fair value recognized in the consolidated statement of operations.